|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
We conclude that the polymorphism of XPD Lys751Gln (rs13181) in combination with smoking contributes to increased risk of pancreatic cancer in the Chinese Han population.
|
29260835 |
2019 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
The genotypes of XPD Asp312Asn (p=0.2493), Lys751Gln (p=0.7547) and promoter -114 (p=0.8702), were not associated with susceptibility for colorectal cancer.
|
27069143 |
2016 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
The ERCC1 rs13181 and XPD rs11615 polymorphisms were not predictive of clinical outcome for HCC patients receiving TACE (both p > 0.05).
|
26918371 |
2016 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results indicated that neither the Asp312Asn nor Lys751Gln XPD polymorphism was related to NHL risk.
|
25962431 |
2015 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
The correlation between ERCC1 polymorphisms (rs11615 and rs3212986) and XPD polymorphisms (rs13181 and rs1799793) with the response rate and overall survival of cancer patients who accept neoadjuvant therapy has been extensively investigated.However, the results are inconclusive.
|
26426637 |
2015 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
A significant association was observed between X</span>PD</span> K75</span>1Q polymorphism and the risk of NPC using conditional logistic regression.
|
26086338 |
2015 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
This is the first study to show that the MnSOD rs4880 and XPD rs13181 polymorphisms may influence the outcome of breast cancer patients receiving adjuvant TAM monotherapy.
|
24716840 |
2014 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our analyses demonstrate that XPD rs13181 may be associated with an increase in the risk of lung cancer among Caucasian populations.
|
24845027 |
2014 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two gene polymorphisms, the MnSOD Val16Ala (rs4880A>G) and the XPD Lys751Gln (rs13181A>C), were analyzed in a cohort of 396 Finnish breast cancer patients by using PCR-RFLP-based methods in a prospective case-control study.
|
24716840 |
2014 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
The Xeroderma pigmentosum group D (XPD, also referred to as excision repair cross complementing gene 2, ERCC2) is one of key genes involved in nucleotide excision repair and two potentially functional polymorphisms of XPD (Asp312Asn and Lys751Gln) have been widely investigated in various cancers including prostate cancer.
|
23771356 |
2014 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
Numerous epidemiological studies have been conducted to investigate the association between Xeroderma pigmentosum complementation group D (XPD) Asp312Asn (rs1799793 G > A) and Lys751Gln (rs13181 A > C) polymorphisms and bladder cancer risk; however, the conclusions remain controversial.
|
24347488 |
2014 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results suggest that the XPD Lys751Gln variant genotype increases the risk of CML.
|
24955348 |
2014 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
In summary, this meta-analysis suggests the XPD Lys751Gln polymorphism is a genetic susceptibility for some cancer types.
|
25113251 |
2014 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
Whether the single nucleotide polymorphism (SNP) Lys751Gln of xeroderma pigmentosum group D(XPD) gene increases susceptibility to head and neck cancer (HNC) is controversial and undetermined.
|
24443924 |
2014 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
We conducted a case-control study to investigate the association of Human apurinic/apyrimidinic (AP) endonuclease (APEX1) Asp148Glu (rs1130409), Xeroderma Pigmentosum group D (XPD) Lys751Gln (rs13181), X-ray repair cross-complementing group 1 (XRCC) Arg399Gln (rs25487) and X-ray repair cross-complementing group 3 (XRCC3) Thr241Met (rs861539) polymorphisms with PE in a Mexican population.
|
24619222 |
2014 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
This is the first study on DNA repair genetic polymorphisms in West Algerian population, and it suggests that the XRCC3 Thr241Met and XPD Lys751Gln polymorphisms may not be associated with the CRC risk in this population.
|
24687779 |
2014 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
We aimed to determine the associations of genetic polymorphisms of excision repair cross-complementation group 1 (ERCC1) rs11615, xeroderma pigmentosum group D (XPD/ERCC2) rs13181, X-ray repair cross complementing group 1 (XRCC1) rs25487, XRCC3 rs1799794, and breast cancer susceptibility gene 1 (BRCA1) rs1799966 from the DNA repair pathway and multiple drug resistance 1 (MDR1/ABCB1) rs1045642 with response to chemotherapy and survival of non-small cell lung cancer (NSCLC) in a Chinese population.
|
24933103 |
2014 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
This meta-analysis suggested that XPD Lys751Gln polymorphism might be a risk factor for AML and Caucasian acute leukemia patients.
|
24486506 |
2014 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
The Xeroderma-Pigmentosum group-D polymorphism at codon-751 (XPD-Lys751Gln) emerged as the most significant independent predictor for death- and progression-risk in our previous study on functional polymorphisms in 122 advanced pancreatic cancer patients treated with cisplatin-docetaxel-capecitabine-gemcitabine and cisplatin-epirubicin-capecitabine-gemcitabine (or EC-GemCap).
|
23390054 |
2013 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
XPD Lys751Gln (A>C) may have inverse predictive and prognostic role in platinum-based treatment of NSCLC according to different ethnicities.
|
24260311 |
2013 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
Significant ESCC risk was observed for XPD Lys751Gln (r</span>s13181</span>) frequency of presence C allele (OR: 1.409, 95% CI: 1.005-1.976) in the three ethnics.
|
21553048 |
2012 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
A meta-analysis based on 9 independent case-control studies involving 3165 PCa patients and 3539 healthy controls for XPD Gln751Lys SNP (single nucleotide polymorphism) and 2555 cases and 3182 controls for Asn312Asp SNP was performed to address this association.
|
23028604 |
2012 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
A statistically significant finding could be seen in noncardia-type gastric cancer for XPD Lys751Gln polymorphism.
|
23028453 |
2012 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, our meta-analysis demonstrated that XPD Lys751Gln polymorphism could be a prediction marker for risk of head and neck cancer.
|
22179996 |
2011 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
In addition XPD rs13181 was also found to be associated with male POAG patients (χ(2) = 12.1 [p < 0.005]), for both dominant (OR = 2.44 [95% CI = 1.33-4.47], p < 0.005) as well as recessive model (OR = 3.62 [95% CI = 1.45-9.01], p < 0.01).
|
21617750 |
2011 |